Samsung Bioepis gets OK to sell Flixabi in Europe

Home > Business > Industry

print dictionary print

Samsung Bioepis gets OK to sell Flixabi in Europe

Samsung Bioepis got a green light from the European Commission to sell its biosimilar drug Flixabi in Europe, the company said on Monday. Flixabi is a biosimiliar product of Janssen’s Remicade.

Samsung already obtained a sales license in Korea for the same product called Renflexis, which treats rheumatis arthritis, ulcerative colitis, Crohn’s disease, spondylarthritis ankylopoietica and psoriatic arthritis. The drug had a market worth about 9 trillion won globally as of 2014.

The new drug will be sold in 31 European countries, including 28 EU member nations and three European Economic Community members - Norway, Iceland and Liechtenstein - with a price tag about 30 to 40 percent lower than Remicade.

Samsung Bioepis already sells another biosimilar product called Bennepali, which refers to the autoimmune disorder treatment drug
Enbrel.

More in Industry

Booze boom

Move over Federer

Hanjin KAL slams largest shareholder, accusing it of peddling lies

Tech firms brief president on state of AI research

Dongsuh recognizes female authors at Scent of Life Awards

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now